Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (8821)	2/22/1999 9:50:00 PM
From: aknahow	Respond to of 17367

"Perhaps. The speculation on this board concerning The Lancet article, coupled with the lack of response from Wall Street, should serve as a reminder that what the Xoma myrmidons consider as important is not necessarily what The Street values as important." It is not necessarily what the street values as important, although I may be only quibbling about your choice of words, but rather a total disinterest or inability to even look at certain types of investments. There are probably more institutional investors following SEPR now when it is over $100 per share than when it was $10. I am not saying XOMA will get to a higher price, but I am saying that if it ever does it will have a greater institutional interest at that time. Sort of a dumb post but bottom line is I am not concerned with the relative lack of institutional interest in XOMA at the present time.